Headquartered in Watertown, MA Fiscal year ends December NASDAQ: EYPT eyepoint.bio
EyePoint, Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for serious retinal diseases. The company's lead product candidate, DURAVYU (vorolanib intravitreal insert), is an investigational sustained-release treatment that combines vorolanib, a selective tyrosine kinase inhibitor with multi-mechanism activity against VEGF receptors, PDGF receptors, and pro-inflammatory IL-6 signaling, delivered via the company's proprietary bioerodible Durasert E technology. DURAVYU is currently in Phase 3 pivotal trials for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), which together represent a combined $15 billion-plus global market opportunity. The company has a legacy of sustained-release drug delivery innovation spanning over three decades, with four FDA-approved products including YUTIQ, ILUVIEN, Retisert, and Vitrasert. EyePoint operates a dedicated 41,000 square foot commercial manufacturing facility in Northbridge, Massachusetts, built to FDA and EMA standards to support potential commercialization of DURAVYU. Vorolanib is licensed exclusively from Equinox Sciences, a Betta Pharmaceuticals affiliate, for the treatment of all ophthalmic diseases outside of China, Macao, Hong Kong, and Taiwan. Updated
Markets took a beating Tuesday as war tensions, surging oil, and the September curse hammered stocks, bonds, and gold all at once. Find out which stocks Wall Street upgraded, downgraded, or initiated…
Wall Street analysts are placing aggressive bets on four clinical-stage biotech companies, with consensus price targets implying gains of up to 384%. These pre-revenue or early-revenue firms carry significant risk, but their…
A public offering of shares this past week prompted a huge purchase from a beneficial owner. Meanwhile, a couple of repeat buyers further boosted their stakes as well.
Even as the earnings-reporting season has begun to slow in the past week, some insiders and beneficial owners were adding to their stakes.
Initial public offerings and a secondary offering inspired insiders to pick up some shares of these biotech companies and others.
As January wound to a close, beneficial owners, executives, and other insiders took advantage of public offerings of stock at these biotech companies.
As the year got underway, biotechs were in focus among the notable insider buying, especially in two companies focused on treatments for the eye.
Warren Buffett's Berkshire Hathaway has bolstered its stake in Occidental Petroleum with a huge purchase of shares. Insider buying is heating up in general.
A biotech stock rallying on encouraging trial results prompted insider buying and selling. A specialty retailer and others saw insider buying too.
EyePoint, Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for serious retinal diseases.
The Wall Street consensus 12-month price target for EYPT is $25.91.
